Braddock J A, Church D B, Robertson I D, Watson A D J
Faculty of Veterinary Science, The University of Sydney, New South Wales, 2006.
Aust Vet J. 2003 Oct;81(10):600-7. doi: 10.1111/j.1751-0813.2003.tb12498.x.
To evaluate the efficacy of trilostane in treating dogs with pituitary-dependent hyperadrenocorticism.
Prospective clinical trial using client-owned dogs with pituitary-dependent hyperadrenocorticism treated at University Veterinary Centre, Sydney from September 1999 to July 2001.
Thirty dogs with pituitary-dependent hyperadrenocorticism treated with trilostane, a competitive inhibitor of 3beta-HSD, were monitored at days 10, 30 and 90 then 3-monthly by clinical examination, tetracosactrin stimulation testing, urinary corticoid:creatinine ratio measurement and by client questionnaire.
Twenty-nine of 30 dogs were successfully treated with trilostane (median dose 16.7 mg/kg; range 5.3 to 50 mg/kg, administered once daily); one responded favourably but died of unrelated disease before full control was achieved.
Trilostane administration controlled pituitary-dependent hyperadrenocorticism in these dogs. It was safe, effective and free of side-effects at the doses used. Most dogs were initially quite sensitive to the drug for 10 to 30 days, then required higher doses until a prolonged phase of stable dose requirements occurred. Urinary corticoid:creatinine ratio was useful in assessing duration of drug effect. Some dogs treated for more than 2 years required reduction or temporary cessation of drug because of iatrogenic hypoadrenocorticism.
评估曲洛司坦治疗垂体依赖性肾上腺皮质功能亢进犬的疗效。
对1999年9月至2001年7月在悉尼大学兽医中心接受治疗的垂体依赖性肾上腺皮质功能亢进的客户自有犬进行前瞻性临床试验。
用曲洛司坦（一种3β - 羟类固醇脱氢酶竞争性抑制剂）治疗30只垂体依赖性肾上腺皮质功能亢进犬，在第10天、30天和90天进行监测，之后每3个月通过临床检查、促肾上腺皮质激素刺激试验、尿皮质醇：肌酐比值测定以及客户问卷调查进行监测。
30只犬中有29只成功用曲洛司坦治疗（中位剂量16.7毫克/千克；范围5.3至50毫克/千克，每日给药一次）；1只反应良好，但在完全控制病情之前死于无关疾病。
曲洛司坦给药可控制这些犬的垂体依赖性肾上腺皮质功能亢进。在所使用的剂量下，它安全、有效且无副作用。大多数犬最初在10至30天对药物相当敏感，然后需要更高剂量，直到出现稳定剂量需求的延长阶段。尿皮质醇：肌酐比值有助于评估药物作用持续时间。一些接受治疗超过2年的犬因医源性肾上腺皮质功能减退需要减少或暂时停用药物。
